



**ROGEL CANCER CENTER**  
UNIVERSITY OF MICHIGAN HEALTH

**Saturday, March 15, 2025**  
**8:00 a.m. - 3:00 p.m.**  
**The Westin Southfield Detroit**  
**and Virtually**

**CME**  
**accredited**

# Emerging Paradigms in Liver Cancer Diagnosis and Treatment

We are happy to host the 2024 Emerging Paradigms in Liver Cancer Diagnosis and Treatment this year at the Westin Southfield Detroit in Southfield, MI, and virtually.

The full-day conference will focus on the full spectrum of primary liver cancers, from early detection, diagnosis, to novel cutting-edge treatments. The program will feature University of Michigan faculty members, with ample opportunities for discussion and interactions.

At the end of this activity, medical professionals will utilize adequate surveillance for hepatocellular carcinoma in patients who are at risk and adequately treat hepatocellular carcinoma and cholangiocarcinoma. They will also identify populations that are appropriate for liver cancer screening and use up-to-date evidence on approved treatments for primary liver cancers. Patients will also receive up to date treatments for primary liver cancer.

**This activity is appropriate for:** Medical Students, Nurse Practitioners, Nurses, Other Healthcare Professionals, Physician Assistants, Physicians

**In the fields of:** Hematology/Oncology, Hepatology, Medical Oncology, Other Healthcare Professions, Pathology, Radiation Oncology, Surgery, Transplant Surgery

### Accreditation and Credit Designation

The University of Michigan Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Michigan Medical School designates this live activity for a maximum of 5.25 AMA PRA Category 1 Credit(s)<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### Agenda

7:30-7:55	Breakfast
7:55-8:00	<b>CME Housekeeping</b> – <i>Neehar Parikh, MD</i>
8:00-8:20	<b>Novel Liquid Biopsy and Imaging Based Screening for HCC</b> – <i>Neehar Parikh, MD</i>
8:20-8:40	<b>Management of PSC and Risk of Cholangiocarcinoma</b> – <i>Nataliya Razumilava, MD</i>
8:20-9:00	<b>Assessing and Preserving Liver Function in Patients with HCC</b> – <i>Alisa Likhitsup, MD</i>
9:00-9:20	<b>Histotripsy for HCC and Liver Tumors</b> – <i>Mishal Mendiratta-Lala, MD</i>
9:20-9:40	<b>Combining LRT and Systemic Therapy for HCC – Recent Evidence and the Horizon</b> – <i>Jared Christensen, MD</i>
9:40-10:00	<b>Adaptive Radiotherapy – Preserving Liver Function while Controlling Tumor</b> – <i>Kyle Cuneo</i>
10:00-10:30	<b>Radioembolization for HCC – Treatment of Choice Across all Stages</b> – <i>Laura Kulik (NW)</i>
10:30-11:00	Break
11:00-11:20	<b>Transplantation for Cholangiocarcinoma and Colorectal Metastases</b> – <i>Christopher Sonnenday, MD</i>
11:20-11:40	<b>Surgical Therapies and Hepatic Arterial Pumps for Metastatic Tumors of the Liver</b> – <i>Ben Ferguson MD</i>
11:40-12:15	<b>Case Discussion</b>
12:15-1:00	Lunch
1:00-1:20	<b>Sequencing Systemic Therapies for Hepatocellular Carcinoma</b> – <i>Oxana Cryslar, MD</i>
1:20-1:40	<b>Systemic Treatment of Advanced Biliary Cancer</b> – <i>Vaibhav Sahai, MBBS</i>
1:40-2:00	<b>The Future of immunotherapy for HCC</b> – <i>Aarathi Mohan, MD</i>
2:00-2:30	<b>Q&amp;A and Wrap Up</b>

### Planning Committee

Vaibhav Sahai, MBBS; Christopher J Sonnenday, MD  
Educational Planner: Neehar D. Parikh, MD

**Info/Register:**

<https://michmed.org/2XPWW>